NCT05082701View on ClinicalTrials.gov

Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

TerminatedOBSERVATIONAL
Enrollment

295

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

October 2, 2023

Study Completion Date

February 22, 2024

Conditions
Cancer
Trial Locations (4)

18103

Lehigh Valley Health Network, Allentown

48109

University of Michigan, Ann Arbor

53792

University of Wisconsin, Madison

70121

Ochsner Clinic Foundation, New Orleans

Sponsors

Lead Sponsor

Strata Oncology
All Listed Sponsors
lead

Strata Oncology

INDUSTRY

NCT05082701 - Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter